BioCentury | May 11, 2018
Clinical News

Bioniz reports Phase Ib data for T cell malignancies candidate

...candidate BNZ-1 led to no serious adverse events or dose-limiting toxicities (DLTs). The company said BNZ-1...
...to an "exposure-related" reduction from baseline in Treg cells, NK cells and CD8+ T cells. BNZ-1...
...lymphocyte leukemia and refractory cutaneous T cell lymphoma (CTCL). Bioniz Therapeutics Inc., Irvine, Calif. Product: BNZ-1...
BioCentury | Mar 2, 2018
Clinical News

Bioniz reports Phase I safety data for BNZ-1

...trial in 18 healthy volunteers showing that single ascending doses of T cell malignancies candidate BNZ-1...
...received a single dose of 0.2, 0.4 , 0.8, 1.6, 3.2 or 6.4 mg/kg IV BNZ-1...
...Bioniz plans to report data from a Phase Ib trial evaluating multiple ascending doses of BNZ-1...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

...modulation and transcription regulation. Among these is the immune modulator BNZ-1 from Bioniz Therapeutics Inc. BNZ-1...
...IL-9 in addition to IL-2 and IL-15. BCIQ contains no other clinical programs against IL-9. BNZ-1’s...
...Bioniz will present Phase I results from a study in healthy volunteers. It is developing BNZ-1...
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...the Leu16 anti-CD20 antibody fused to IL-2 Non-Hodgkin's lymphoma (NHL) Phase I/II Bioniz Therapeutics Inc. BNZ-1...
BioCentury | Aug 1, 2016
Financial News

Bioniz raises $13M in series A round

...participated. Bioniz said it expects to begin a Phase I study "shortly" of lead candidate BNZ-1...
Items per page:
1 - 5 of 5